Imperial College London

Professor Paul M. Matthews

Faculty of MedicineDepartment of Brain Sciences

Edmond and Lily Safra Chair, Head of Department



+44 (0)20 7594 2855p.matthews




Ms Siobhan Dillon +44 (0)20 7594 2855




E502Burlington DanesHammersmith Campus






BibTex format

author = {Tzimopoulou, S and Cunningham, VJ and Nichols, TE and Searle, G and Bird, NP and Mistry, P and Dixon, IJ and Hallett, WA and Whitcher, B and Brown, AP and Zvartau-Hind, M and Lotay, N and Lai, RYK and Castiglia, M and Jeter, B and Matthews, JC and Chen, K and Bandy, D and Reiman, EM and Gold, M and Rabiner, EA and Matthews, PM},
doi = {10.3233/978-1-60750-793-2-627},
journal = {Advances in Alzheimer's Disease},
pages = {627--642},
title = {Validation and pilot application of [ <sup>18</sup>F]FDG-PET in evaluation of a metabolic therapy for Alzheimer's disease},
url = {},
volume = {2},
year = {2011}

RIS format (EndNote, RefMan)

AB - Here we describe methods for application of quantitative fluorodeoxyglucose positron emission tomography ([ 18F]FDG-PET) measures of brain glucose metabolism in multi-centre clinical trials for Alzheimer's disease. We validated methods and demonstrated their use in the context of a treatment trial with the PPARγ agonist Rosiglitazone XR versus placebo in mild to moderate AD patients. Novel quantitative indices related to the combined forward rate constant for [ 18F]FDG uptake \(({K}-{i}^{index})\) and to the rate of cerebral glucose utilization \((CM{R}-{glu}^{index})\) were applied. Active treatment was associated with a sustained but not statistically significant trend from the first month for higher mean values in both. However, neither these nor another analytical approach recently validated using data from the Alzheimer's Disease Neuroimaging Initiative suggested that active treatment decreased the progression of decline in brain glucose metabolism. Rates of brain atrophy were similar between active and placebo groups and measures of cognition also did not demonstrate clear group differences. Our study demonstrates the feasibility of using [ 18F]FDG-PET as part of a multi-centre therapeutics trial and describes new measures that can be employed. It suggests that Rosiglitazone is associated with an early increase in whole brain glucose utilisation, but not with any biological or clinical evidence for slowing progression over the period of study in the selected patient group. © 2011 The authors and IOS Press. All rights reserved.
AU - Tzimopoulou,S
AU - Cunningham,VJ
AU - Nichols,TE
AU - Searle,G
AU - Bird,NP
AU - Mistry,P
AU - Dixon,IJ
AU - Hallett,WA
AU - Whitcher,B
AU - Brown,AP
AU - Zvartau-Hind,M
AU - Lotay,N
AU - Lai,RYK
AU - Castiglia,M
AU - Jeter,B
AU - Matthews,JC
AU - Chen,K
AU - Bandy,D
AU - Reiman,EM
AU - Gold,M
AU - Rabiner,EA
AU - Matthews,PM
DO - 10.3233/978-1-60750-793-2-627
EP - 642
PY - 2011///
SN - 2210-5727
SP - 627
TI - Validation and pilot application of [ <sup>18</sup>F]FDG-PET in evaluation of a metabolic therapy for Alzheimer's disease
T2 - Advances in Alzheimer's Disease
UR -
VL - 2
ER -